AARD

Aardvark Therapeutics, Inc. Common Stock

Recommendation Details

PortfolioMicrocap Short

DateOct 29, 2026

ForecastQ Daily Probabilities

45.9%

79.6%

85.1%

Company Description

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Recent News & Events

AARD is in a post-catalyst freefall after exploratory Phase 3 HERO/OLE data showed only modest, non-definitive efficacy, driving a ~65% single-day collapse; the FDA hold lift is now fully digested and the next leg depends on FDA meeting timing and 2027 restart, leaving near-term sentiment decisively negative with high volatility risk.

Clinical Data Readout (Exploratory)

Exploratory HERO/OLE data show only modest efficacy vs placebo

Aardvark reported exploratory data from its early-terminated Phase 3 HERO trial (67 of 90 planned participants) and OLE, showing only a modest HQ-CT reduction vs placebo at week two of dose escalation, with hunger scores rebounding to near baseline within two weeks of stopping ARD-101 and less rebound on placebo. The company explicitly stated the partial data are insufficient to draw definitive conclusions. This removed the primary efficacy thesis and triggered a ~65% single-day stock collapse, with continued selling into the following session.

Aardvark Therapeutics Press Release (GlobeNewswire)

Regulatory Update (Clinical Hold Lifted)

FDA lifts full clinical hold on ARD-101 IND

The FDA lifted the clinical hold placed in May 2026 on the ARD-101 IND for hyperphagia in Prader-Willi syndrome, following additional ECG and in vitro cardiac sodium channel studies that showed no cardiac events at 200 mg and 400 mg BID. The stock initially jumped ~21% after-hours on the news, but this positive catalyst was fully overwhelmed by the subsequent negative efficacy data, making its residual near-term price impact largely neutralized.

Aardvark Therapeutics Press Release (GlobeNewswire)

Clinical Development Timeline / FDA Meeting

Company to request FDA meeting on new Phase 3 design; restart in 2027

Management plans to request an FDA meeting to align on a new Phase 3 trial design and expects to resume PWS clinical activities only in 2027, at a lower dose than the 800 mg BID studied. The multi-quarter gap to any new data or regulatory milestone removes near-term positive catalysts and leaves the stock exposed to continued de-risking and financing overhang.

Aardvark Therapeutics Press Release (GlobeNewswire)

AARD

AARD

Company Information

Recommendation Details

Company Description

Recent News & Events

Exploratory HERO/OLE data show only modest efficacy vs placebo

FDA lifts full clinical hold on ARD-101 IND

Company to request FDA meeting on new Phase 3 design; restart in 2027